

FOI 1723

15th June 2023

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

Question 1.

How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:

- Adalimumab - Humira
- Adalimumab Biosimilar
- Filgotinib
- Golimumab
- Infliximab - Remicade
- Infliximab Biosimilar
- Ozanimod
- Tofacitinib
- Upadacitinib
- Ustekinumab
- Vedolizumab
- Vedolizumab Injections ONLY (pre-filled pens or syringes)

Answer 1.

• Adalimumab - Humira	7
• Adalimumab Biosimilar	177
• Filgotinib	0
• Golimumab	<5
• Infliximab - Remicade	0
• Infliximab Biosimilar	89
• Ozanimod	0
• Tofacitinib	6
• Upadacitinib	<5
• Ustekinumab	102
• Vedolizumab	53
• Vedolizumab Injections ONLY (pre-filled pens or syringes)	48

The Trust has a legal duty to protect patient confidentiality and, in line with this duty, the figure <5 has been provided where figures are very low. This is because of the potential risk of identification of an individual. In reaching this decision the Trust has taken into account the small geographical area which the Trust serves and the sensitivity of the

information requested. In addition the Trust has taken into account the fact that all information disclosed in response to an FOI is disclosed to the 'world at large' and is published on the Trust website.

S 40 (2) (third party information) of the Freedom of Information Act 2000 has been applied to exempt the redacted information from disclosure. The Trust does not consider the disclosure of the redacted information to be fair to the individuals concerned as there is the potential risk of identification of an individual(s) which they would not expect, and which would therefore breach the fairness element of the first principle of the Data Protection Act 2018.

Question 2.

If you are able to link patient treatment to a disease, could you please provide the number of patients treated in the last 3 months for Ulcerative Colitis ONLY with the following biologic drugs:

- Adalimumab - Humira
- Adalimumab Biosimilar
- Filgotinib
- Golimumab
- Infliximab - Remicade
- Infliximab Biosimilar
- Ozanimod
- Tofacitinib
- Upadacitinib
- Ustekinumab
- Vedolizumab
- Vedolizumab Injections ONLY (pre-filled pens or syringes)

Answer 2.

• Adalimumab - Humira	0
• Adalimumab Biosimilar	61
• Filgotinib	0
• Golimumab	<5
• Infliximab - Remicade	0
• Infliximab Biosimilar	52
• Ozanimod	0
• Tofacitinib	6
• Upadacitinib	<5
• Ustekinumab	26
• Vedolizumab	31
• Vedolizumab Injections ONLY (pre-filled pens or syringes)	29

The Trust has a legal duty to protect patient confidentiality and, in line with this duty, the figure <5 has been provided where figures are very low. This is because of the potential risk of identification of an individual. In reaching this decision the Trust has taken into account the small geographical area which the Trust serves and the sensitivity of the information requested. In addition the Trust has taken into account the fact that all



Southern Health and Social Care Trust

information disclosed in response to an FOI is disclosed to the 'world at large' and is published on the Trust website.

S 40 (2) (third party information) of the Freedom of Information Act 2000 has been applied to exempt the redacted information from disclosure. The Trust does not consider the disclosure of the redacted information to be fair to the individuals concerned as there is the potential risk of identification of an individual(s) which they would not expect, and which would therefore breach the fairness element of the first principle of the Data Protection Act 2018.

Question 3.

Does your trust participate in clinical trials for the treatment of Ulcerative Colitis? If so, please provide the total number of patients taking part in any Ulcerative Colitis study.

Answer 3.

The SHSCT does not participate in clinical trials for the treatment of Ulcerative Colitis.

Email: Foi.Team@Southerntrust.hscni.net